StockData
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. (SPRO) stock

SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3046% below fair value
$0.87−0.03 (-3.03%)

Close on Nov 18, 2026Market cap $50.90MP/E 21.9Yield –

Spero Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Spero Therapeutics's free cash flow for the twelve months ending Dec 31, 2020 was -$86.03M. For fiscal 2020 it was -$86.03M. The highest annual figure on record is -$9.84M in fiscal 2015.

Annual free cash flow

PeriodPeriod endValueChange
FY2020Dec 31, 2020-$86.03M–
FY2019Dec 31, 2019-$50.33M–
FY2018Dec 31, 2018-$42.06M–
FY2017Dec 31, 2017-$39.14M–
FY2016Dec 31, 2016-$29.79M–
FY2015Dec 31, 2015-$9.84M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2021Sep 30, 2021-$4.95M–
Q4 FY2020Dec 31, 2020-$16.40M–
Q3 FY2020Sep 30, 2020-$21.32M–
Q2 FY2020Jun 30, 2020-$24.91M–
Q1 FY2020Mar 31, 2020-$23.41M–
Q4 FY2019Dec 31, 2019-$17.50M–
Q3 FY2019Sep 30, 2019-$9.68M–
Q2 FY2019Jun 30, 2019-$12.16M–
Q1 FY2019Mar 31, 2019-$11.01M–
Q4 FY2018Dec 31, 2018-$15.92M–
Q4 FY2016Dec 31, 2016-$9.47M–

More Spero Therapeutics figures

See a number that looks wrong?